Drug Profile
Research programme: diabetes therapies - Theravalues
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Theravalues Corporation
- Class
- Mechanism of Action AKR1B1 protein inhibitors; Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Japan
- 17 May 2012 Preclinical trials in Type-2 diabetes mellitus in Japan (unspecified route)